Brukinsa 80Mg Bottle Of 120 Capsules

• Mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Waldenström's macroglobulinemia (WM).
• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• Relapsed or refractory follicular lymphoma (FL) after at least two prior lines of systemic therapy, in combination with obinutuzumab.

• Low white blood cell count (neutropenia), increasing the risk of serious infections
• Low platelet count (thrombocytopenia), causing easy bruising or bleeding
• Upper respiratory tract infections (cold, sore throat, runny nose)
• Bleeding and bruising (haemorrhage), which may occur anywhere in the body
• Muscle and bone pain (musculoskeletal pain)

• Skin rash and bruising
• Diarrhoea and constipation
• Fatigue and weakness
• Nausea
• High blood pressure (hypertension)
• Headache and dizziness
• Cough and shortness of breath (dyspnea)
• Fever (pyrexia)
• Itching (pruritus)
• Swelling in the feet or legs (peripheral oedema)
• Pneumonia (lung infection)
• Development of a second primary cancer, most commonly non-melanoma skin cancer

• Serious or fatal bleeding including bleeding in the brain (intracranial haemorrhage) or stomach and intestines (gastrointestinal haemorrhage).
• Serious and life-threatening infections including pneumonia, sepsis, and opportunistic infections.
• Severe drop in blood counts (cytopenias) including dangerous levels of neutropenia, thrombocytopenia, and anaemia.
• Cardiac arrhythmias including atrial fibrillation or flutter, causing palpitations, dizziness, or chest discomfort.
• Liver damage including drug-induced liver injury (DILI), with symptoms of yellowing of the skin or eyes, dark urine, or abdominal discomfort.

Other General Warnings

• You notice any unusual bleeding including prolonged nosebleeds, blood in the urine, coughing up blood, blood in stools, or unexpected bruising, as Brukinsa capsule can cause serious or fatal haemorrhage, particularly in patients also taking blood thinners or antiplatelet medicines.
• You develop fever, chills, persistent cough, or any signs of infection, as Brukinsa capsule can significantly lower white blood cell counts and increase the risk of serious life-threatening infections including pneumonia, sepsis, and opportunistic infections.
• You have a history of hepatitis B infection, as Brukinsa capsule can trigger reactivation of hepatitis B; antiviral prophylaxis may be required before starting treatment.
• You develop palpitations, irregular heartbeat, dizziness, fainting, shortness of breath, or chest discomfort, as Brukinsa capsule can cause cardiac arrhythmias including atrial fibrillation and ventricular arrhythmias requiring medical management.
• You notice yellowing of the skin or eyes, dark urine, or abdominal discomfort, as Brukinsa capsule can cause serious liver damage including drug-induced liver injury (DILI) that may require treatment discontinuation.
• You are planning surgery or an invasive dental procedure, as Brukinsa capsule increases the risk of bleeding and a temporary treatment pause of 3 to 7 days before and after surgery may be required.
• You have severe liver disease (Child-Pugh C), as a dose reduction from the standard dose is required for this condition.
• You notice any new, changing, or unusual skin lesions, as Brukinsa capsule is associated with an increased risk of new skin cancers and regular skin monitoring with sun protection is recommended throughout treatment.
• You have a history of cardiac conditions including hypertension, atrial fibrillation, or other arrhythmias, as Brukinsa capsule may worsen existing cardiac problems.
• You are a man or woman planning to have children in the future, as Brukinsa capsule may affect fertility based on findings in animal studies.
• Before receiving any live vaccines during treatment, as your immune response may be significantly weakened.

• Take Brukinsa capsule exactly as prescribed by your doctor, with or without food.
• Swallow the capsules whole with a glass of water; do not open, break, or chew them.
• If you miss a dose, take it as soon as possible on the same day and return to your normal schedule the following day.
• Never change your dose or stop taking Brukinsa capsule without first consulting your doctor.

• Store at room temperature, 20-25°C (68-77°F).
• Do not freeze.
• Keep out of reach of children and pets.

• Swallow Brukinsa capsule capsules whole with a glass of water; never open, break, or chew them.
• Contact your doctor immediately if you notice any unusual bleeding such as blood in the urine, prolonged nosebleeds, coughing up blood, or blood in stools, as this medicine can cause serious or fatal haemorrhage.
• Tell your doctor right away if you develop fever, persistent cough, chills, or any signs of infection, as Brukinsa capsule can significantly lower your white blood cell count and increase the risk of serious infections.
• Report any palpitations, irregular heartbeat, dizziness, fainting, or chest discomfort to your doctor, as Brukinsa capsule has been associated with cardiac arrhythmias including atrial fibrillation.
• Use broad-spectrum sunscreen and wear protective clothing outdoors, and attend regular skin check-ups, as Brukinsa capsule is associated with an increased risk of new skin cancers.
• Tell your doctor well in advance of any planned surgery or dental procedure, as a temporary treatment pause may be needed to reduce the risk of bleeding.
• Women of childbearing potential must use effective contraception during treatment and for 1 week after the last dose; men must also use effective contraception during treatment and for 1 week after the last dose.
• Inform all your doctors, dentists, and emergency care providers that you are taking Brukinsa capsule, as it affects your blood counts and interacts with many medicines.

Overdose

• There is no specific antidote for a Brukinsa capsule overdose. If you think you have taken too much of this medicine, contact your doctor or go to the nearest emergency department right away. Your doctor will stop the medicine and provide supportive monitoring and care as needed.
• Since Brukinsa capsule is taken at home, always keep it in its original container and never share it with others.

Missed a Dose

• If you miss a dose of Brukinsa capsule, take it as soon as you remember on the same day and then return to your normal schedule the following day. If you do not remember until the next day, skip the missed dose entirely.
• Do not take extra capsules to make up for a missed dose. If you are unsure what to do, contact your doctor or pharmacist for advice.

Interactions with other medicines

• Avoid strong CYP3A inducers such as rifampicin, carbamazepine, phenytoin, and St. John's Wort, as these can significantly reduce the effectiveness of Brukinsa capsule by lowering its blood levels.
• Avoid moderate CYP3A inducers such as rifabutin and efavirenz if possible; if they cannot be avoided, your doctor will increase the dose of Brukinsa capsule.
• Strong and moderate CYP3A inhibitors such as ketoconazole, posaconazole, voriconazole, and clarithromycin can significantly raise Brukinsa capsule blood levels; your doctor will reduce your dose if these medicines are needed.
• Brukinsa capsule can raise digoxin levels (a heart medicine); your doctor will monitor you closely if both medicines are taken together.
• Always tell your doctor about all medicines, supplements, vitamins, and herbal products you are taking before starting treatment.

Interactions with food items

• Brukinsa capsule can be taken with or without food, as food does not significantly affect the overall amount of medicine absorbed into the body.
• Eating small, light, and frequent meals can help manage nausea and diarrhoea, which are common side effects.
• Drink enough water and fluids throughout the day to support overall health during treatment.
• Avoid alcohol during treatment, as it can worsen fatigue, diarrhoea, and may increase the risk of bleeding.